scPharmaceuticals Inc. Common Stock
SCPH
SCPH: scPharmaceuticals Inc is a pharmaceutical company. Its pipeline includes products in various stages of clinical and non-clinical development. It focuses on pharmaceutical products in the cardiovascular and infectious disease therapeutic areas. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
moreShow SCPH Financials
Recent trades of SCPH by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by SCPH's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Concentrated liquid pharmaceutical formulations of furosemide Feb. 07, 2023
-
Patent Title: Concentrated liquid pharmaceutical formulations of furosemide Jan. 24, 2023
-
Patent Title: Concentrated liquid pharmaceutical formulations of furosemide Nov. 15, 2022
-
Patent Title: Pharmaceutical formulations for subcutaneous administration of furosemide Sep. 06, 2022
-
Patent Title: Pharmaceutical formulations for subcutaneous administration of furosemide Apr. 30, 2019
-
Patent Title: Pharmaceutical formulations for subcutaneous administration of furosemide Feb. 06, 2018
Federal grants, loans, and purchases
Followers on SCPH's company Twitter account
Number of mentions of SCPH in WallStreetBets Daily Discussion
Recent insights relating to SCPH
Recent picks made for SCPH stock on CNBC
ETFs with the largest estimated holdings in SCPH
Flights by private jets registered to SCPH